Stephen Lowe1, Krishna P Bhat2, Adriana Olar1,3. 1. Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina. 2. Deparment of Translational Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Departments of Pathology and Laboratory Medicine, Medical University of South Carolina & Hollings Cancer Center, Charleston, South Carolina.
Abstract
BACKGROUND: Glioblastoma (GB) is the most aggressive primary brain tumor, historically resistant to treatment, and with overall fatal outcome. RECENT FINDINGS: Recently, several molecular subgroups and rare genetic alterations have been described in GB. In this review article, we will describe the current clinical management of patients with GB in the United States, discuss selected next-generation molecular-targeted therapies in GB, and present ongoing clinical trials for patients with GB. This review is intended for clinical and preclinical researchers who conduct work on GB and would like to understand more about the current standard of treatment of GB patients, historical perspectives, current challenges, and ongoing and upcoming clinical trials. CONCLUSIONS: GB is an extremely complex disease, and despite recent progress and advanced therapeutic strategies, the overall patient's prognosis remains dismal. Innovative strategies and integrative ways of approach to disease are urgently needed.
BACKGROUND:Glioblastoma (GB) is the most aggressive primary brain tumor, historically resistant to treatment, and with overall fatal outcome. RECENT FINDINGS: Recently, several molecular subgroups and rare genetic alterations have been described in GB. In this review article, we will describe the current clinical management of patients with GB in the United States, discuss selected next-generation molecular-targeted therapies in GB, and present ongoing clinical trials for patients with GB. This review is intended for clinical and preclinical researchers who conduct work on GB and would like to understand more about the current standard of treatment of GB patients, historical perspectives, current challenges, and ongoing and upcoming clinical trials. CONCLUSIONS: GB is an extremely complex disease, and despite recent progress and advanced therapeutic strategies, the overall patient's prognosis remains dismal. Innovative strategies and integrative ways of approach to disease are urgently needed.
Authors: Barbara Fazeny-Dörner; Catharina Wenzel; Mario Veitl; Maria Piribauer; Karl Rössler; Karin Dieckmann; Karl Ungersböck; Christine Marosi Journal: Anticancer Drugs Date: 2003-04 Impact factor: 2.248
Authors: Devendra Singh; Joseph Minhow Chan; Pietro Zoppoli; Francesco Niola; Ryan Sullivan; Angelica Castano; Eric Minwei Liu; Jonathan Reichel; Paola Porrati; Serena Pellegatta; Kunlong Qiu; Zhibo Gao; Michele Ceccarelli; Riccardo Riccardi; Daniel J Brat; Abhijit Guha; Ken Aldape; John G Golfinos; David Zagzag; Tom Mikkelsen; Gaetano Finocchiaro; Anna Lasorella; Raul Rabadan; Antonio Iavarone Journal: Science Date: 2012-07-26 Impact factor: 47.728
Authors: Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff Journal: Science Date: 2013-04-04 Impact factor: 47.728
Authors: Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Sakthi Lenin; Elise Ponthier; Kaitlin G Scheer; Erica C F Yeo; Melinda N Tea; Lisa M Ebert; Mariana Oksdath Mansilla; Santosh Poonnoose; Ulrich Baumgartner; Bryan W Day; Rebecca J Ormsby; Stuart M Pitson; Guillermo A Gomez Journal: Int J Mol Sci Date: 2021-04-21 Impact factor: 5.923
Authors: Antonio C Fuentes-Fayos; Miguel E G-García; Jesús M Pérez-Gómez; Annabel Peel; Cristóbal Blanco-Acevedo; Juan Solivera; Alejandro Ibáñez-Costa; Manuel D Gahete; Justo P Castaño; Raúl M Luque Journal: Int J Mol Sci Date: 2022-01-20 Impact factor: 5.923